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 Abstract                                                                                                            
Background: Stroke is the third leading cause of invalidism and 
death in industrialized countries. There are conflicting reports 
about the effects of Angiotensin II on ischemia-reperfusion brain 
injuries and most data have come from chronic hypertensive 
rats. In this study, hypotensive and non-hypotensive doses of 
candesartan were used to investigate the effects of angiotensin 
II AT1 receptor blockade by transient focal cerebral ischemia in 
normotensive rats.
Methods: In this experimental study, 48 male Sprague-Dawley 
rats were randomly divided into four groups (n=12). Sham group, 
the control ischemic group, and two ischemic groups received 
candesartan at doses of 0.1 or 0.5 mg/kg at one hour before 
ischemia. Transient focal cerebral ischemia was induced by 60 
minutes occlusion of the middle cerebral artery, followed by 24 
h reperfusion. The neurological deficit score was evaluated at 
the end of the reperfusion period. The total cortical and striatal 
infarct volumes were determined using triphenyltetrazolium 
chloride staining technique. Tissue swelling was calculated for 
the investigation of ischemic brain edema formation.
Results: In comparison with the control ischemic group, AT1 
receptor blockade with both doses of candesartan (0.1 or 0.5 mg/
kg) significantly improved neurological deficit and lowered cortical 
and striatal infarct sizes. In addition, pretreatment with candesartan 
significantly reduced ischemia induced tissue swelling.
Conclusion: Angiotensin II by stimulating AT1 receptors, 
participates in ischemia-reperfusion injuries and edema formation. 
AT1 receptor blockade with candesartan decreased ischemic brain 
injury and edema and improved neurological outcome.
Please cite this article as: Panahpour H, Nekooeian AA, Dehghani GhA. Blockade 
of Central Angiotensin II AT1 Receptor Protects the Brain from Ischemia/
Reperfusion Injury in Normotensive Rats. Iran J Med Sci. 2014;39(6):536-542.
Keywords ● Angiotensin II ● Angiotensin AT1 receptor ● 
Candesartan ● Stroke ● Rat
Original Article
 Introduction                                                                                         
Ischemic stroke remains one of the main illnesses with a major health 
and economic impact, and greatly consumes medical resources. 
With a mortality rate of around 30%, stroke remains the third leading 
cause of invalidism and death in industrialized countries. Ischemic 
brain injury is the result of a complex sequence of pathophysiological 
events that develops over time and space.1 Brain edema is a life-
threatening complication of cerebral infarction and aggravates 
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the primary ischemic injury to the brain.2,3 It is 
suggested that the prevention of ischemic brain 
edema formation reduces neuronal injury following 
cerebral ischemia.4
Beside its multiple physiological functions, 
renin-angiotensin system (RAS) has been 
implicated in pathogenesis and outcome of 
ischemic injuries in vital organs such as heart5 
and kidney.6 Furthermore, it is suggested that 
RAS may contribute in stroke related pathogenic 
mechanisms and involve in the ischemic brain 
damage.7 However, the role of RAS in ischemic 
brain injuries is controversial. Initial studies 
suggested a protective role for RAS activity in 
cerebral ischemia but later reports postulated 
a correlation between Angiotensin (Ang) II and 
the severity of ischemic injury. Previous studies 
demonstrated that inhibition of angiotensin 
converting enzyme by enalapril pretreatment8 and 
treatment.9 Furthermore, the reduction of Ang II 
improved neurological outcome and reduced 
brain injuries in animal models of focal cerebral 
ischemia. Most of the physiological action of Ang 
II has been shown to be mediated by the AT1 
receptors.10 Consequently, this study is designed 
to investigate the role of RAS activity and its 
effector peptide, Ang II in conjunction with AT1 
receptors in brain injuries and edema following 
transient focal cerebral ischemia in rats. 
In this study, candesartan as an AT1 antagonist 
was used for AT1 receptor blocking. It has been 
demonstrated that candesartan can easily 
penetrate the blood brain barrier (BBB) to inhibit 
the effects of central Ang II. The long-lasting 
blockade of central AT1 receptors by candesartan 
may be attributed to its tight binding and slow 
dissociation from AT1 receptors.
11,12 Therefore, the 
effective and long-lasting blockade of central AT1 
receptors is produced by candesartan. 
The present study uses an intraluminal filament 
method that induces transient focal cerebral ischemia 
by middle cerebral artery occlusion (MCAO) in a 
rat.8,9 This model is less invasive and reperfusion 
of the ischemic region is feasible. It is comparable 
with human stroke, in which spontaneous or 
drug-induced reperfusion occurs. Furthermore, 
most data about the participation of RAS in 
cerebral ischemia have originated from chronic 
hypertensive rats.13-15 Pathologic remodeling 
of cerebral vessels that occur during chronic 
hypertension are believed to interfere with the 
outcomes of neuroprotective agents.15 To exclude 
these possibilities, the model of transient focal 
cerebral ischemia in normotensive rats was used. 
 Materials and Methods                                                                                        
Male Sprague-Dawley rats (300-380g) were 
obtained from the central animal shelter facility of 
Shiraz Medical Sciences University (Shiraz, Iran). 
All protocols of the study were approved by the 
Institutional Animal Ethics Committee of Shiraz 
University of Medical Sciences, which follows the 
National Institutes of Health guidelines for care 
and use of animals. Animals were housed at room 
temperature of 22-24°C, humidity of 40-60% and 
light period of 07.00-19.00 controlled environments. 
The animals had access to tap water and rat chow, 
but only had free access to tap water on the night 
before surgery. They were anesthetized with IP 
injections of chloral hydrate (400 mg/kg). Two 
temperature probes were inserted into the left 
temporalis muscle and rectum to monitor head 
and core temperatures. Two separate heating 
lamps were used to keep the core and cranial 
temperatures at 37±0.5°C.
Experimental Design and Protocol
Group I (sham, n=12): rats underwent surgery in 
the neck region and received a single IV injection of 
the vehicle (1 ml/kg, 0.1 normal sodium carbonate 
solution) without being exposed to MCAO. 
Group II (control ischemic; n=12): rats received 
a single IV injection of the vehicle 1 h before 
MCAO. Brain ischemia achieved by 60 minutes 
MCAO followed by 24 h reperfusion.
Group III (candesartan pretreated ischemic 
rats with 0.1 mg/kg; n=12): rats received a single 
IV injection of 0.1 mg/kg of candesartan (Toronto 
Research Chemical Inc, Canada) 1 h prior to 
MCAO. All procedures, which were performed on 
rats of group II, were also repeated for this group. 
Group IV (candesartan pretreated ischemic 
rats with 0.5 mg/kg; n=12): rats of this group 
received a single IV injection of 0.5 mg/kg of 
candesartan 1 h before induction of MCAO. Other 
procedures were similar to groups II and III. 
In some randomly selected rats from each 
group (n=4), the tail artery was cannulated to record 
mean arterial blood pressure (MAP) and withdrew 
0.3 ml arterial blood for the measurements of 
physiological parameters including pH, PO2, PCO2, 
SaO2 and blood glucose. Blood sampling was done 
at 10 minutes before and 30 minutes after MCAO 
and 10 minutes after the start of reperfusion. Other 
animals from each group (n=8) were used for the 
determination of neurological outcome, infarct size 
and tissue swelling.
Induction of Transient Focal Cerebral Ischemia
Transient focal cerebral ischemia induced 
by occluding the middle cerebral artery (MCA) 
using the intraluminal filament method described 
previously.16 In brief, a midline incision was 
performed in the ventral surface of the neck. 
Afterwards, the right common carotid artery 
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(CCA) was freed from surrounding fascia and 
vagus nerve dissected to reach the bifurcation 
of external and internal carotid arteries. The 
occipital artery and superior thyroid branches of 
the external carotid artery (ECA) were isolated 
and closed. Subsequently, ECA was ligated 
permanently and the internal carotid artery (ICA) 
dissected free to the level of pterygopalatine 
artery. Afterwards, a poly-L-Lysine coated 
nylon 3-0 monofilament thread was inserted, 
via proximal ECA, into ICA and gently moved 
forward to the circle of Willis to reach and occlude 
MCA. After 60 minutes ischemia, reperfusion was 
established by pulling out the nylon thread. After 
reperfusion phase, the vessels were then tied 
up and the incisions were sutured. The animals 
were allowed to recover from anesthesia, and 
were then kept in separate cages. Twenty-four 
hours after termination of MCAO, neurological 
activity was evaluated and animals were then 
sacrificed under deep anesthesia by a bolus of 
injection of sodium thiopental solution. The brain 
was removed and prepared for the determination 
of the infarct volumes.
Measurement of Infarct Size and Tissue Swelling
The brain was gently removed and placed 
in ice-cold saline for 5 minutes to solidify for 
coronal sectioning using a brain matrix. The 
brain was sectioned into six 2-mm-thick slices. 
The slices were stained by immersing in 10 ml 
2% Triphenyltetrazolium chloride (TTC) solution, 
which had been placed in a water bath of 37°C for 
30 minutes. The stained slices were kept in 10% 
buffered formalin for 24 hours. Afterwards, the 
slices were photographed with a digital camera 
connected to a PC computer. Infarct area of 
each slice was measured in mm2 using an Image 
Analyzer Software (NIH Image Analyzer). The 
infarct volume in mm3 of each slice was calculated 
by multiplying the obtained infarct areas by the 
slice thickness. Finally, the infarct volumes of 
six slices were summed up to calculate the total 
infarct size of each brain.17 Since brain edema 
could significantly affect the accuracy of the 
estimation of the infarct volumes, the calculated 
infarct volumes were then corrected for brain 
edema according to equation 1. The tissue 
swelling induced in the lesioned hemispheres 
of the TTC staining method was evaluated as in 
equation 2.15
(1) Corrected infarction volume=[NHV–(LHV–MLV)]
(2) %Tissue swelling=[(LHV–NHV)/NHV] ×100 
NHV: Non-lesioned hemisphere volume (left 
hemisphere)
LHV: Lesioned hemisphere volume (right 
hemisphere)
MLV: Measured lesion volume
Statistical Analysis
All statistical analyses were performed by 
SPSS software (SPSS for Windows version 20) 
Most of the data are presented as mean±SEM 
and the significance of differences was 
evaluated using one-way analysis of variance 
(ANOVA) followed by Tukey’s test. Neurological 
deficit values are given as median values with 
quartile range (25-75%). Significant differences 
were analyzed by Kruskal–Wallis one-way 
ANOVA test. Statistical significance was 
accepted at P<0.05.
 Results                                                                                      
Physiological Parameters
The physiological parameters measured 
in this study such as PaO2, SaO2, PaCO2, pH, 
blood glucose, head and core temperatures are 
summarized in table 1. There was no significant 
difference between these parameters using intra-
groups or inter-groups comparison. 
Table 1: Physiological parameters in the studied groups
 Parameters
Name
Pre ischemia During Occlusion During Reperfusion
group II group III group IV group II group III group IV group II group III group IV
PaO2(mmHg) 116± 8 105±21 127±11 103±11 105±5 110±15 114±9 114±11 104±12
SaO2(%) 98±0.4 96.5±1.3 98.3±0.4 96.7±1 97.3±0.3 96.6±1.8 97.8±0.5 97.9±0.6 96.3±1.8
PaCO2(mmHg) 42.5±0.7 40±2.8 42.1±1.4 40.2±0.7 39.9±2.2 39±2 41.1±1.6 41.1±2 41.2±1.6
pH 7.32±0.01 7.33±0.01 7.31±0.01 7.3±0.01 7.31±0.01 7.3±0.02 7.3±0.01 7.32±0.01 7.29±0.01
 Blood Glucose
(mg/dl)
137±15 141±10 124±17 129±10 135±9 121±16 133±8 142±14 122±18
Body Tem-
perature
37.1±0.06 37.3±0.15 37.3±0.14 37.4±0.1 37.4±0.09 37±0.05 37.2±0.1 37.5±0.09 37.4±0.09
Head Tem-
perature
37.1±0.05 37.4±0.1 37.4±0.13 37.5±0.09 37.4±0.08 37.5±0.1 37.4±0.1 37.5±0.05 37.5±0.09
MAP (mmHg) 91.9±3 78.3±5 57±11* 92.3±2 83.5±5 69±3 92±3 74.5±8 68.4± 9
Values are mean±SEM of four rats in each group; *Significant compared with the respective control rats (group II), P<0.05. 
MAP: mean arterial blood pressure
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Mean Arterial Blood Pressure
There was no significant difference among the 
mean arterial blood pressure (MAP) of ischemia 
reperfused (IR) rats received vehicle (group II) or 
candesartan at 0.1 mg/kg (group III) at 10 minutes 
before MCAO, 30 minutes after MCAO or 10 
minutes after the onset of reperfusion. Whereas 
the MAP of IR rats received candesartan at 0.5 
mg/kg (group IV) were significantly lower than 
those of IR rats received vehicle only at 10 
minutes before MCAO (P=0.03, table 1).
Neurological Deficit Score (NDS) 
The NDS of IR rats received vehicle were 
significantly higher than that of sham-operated 
rats. However, there were significant improvements 
in NDS of ischemic rats treated with 0.1 mg/kg or 
0.5 mg/kg of candesartan. The median (25–75% 
quartile range) of the total deficit score for control 
ischemic rats (group II) was 3 (2–3) compared 
with 1 (1.0–2) in group III (P=0.008) and 1 (1.0–2) 
in group IV (P=0.003) that received candesartan 
at 0.1 mg/kg or 0.5 mg/kg respectively (Kruskal–
Wallis one-way ANOVA test).
Cerebral Infarct size 
The sham-operated rats had no cerebral 
infarction. In comparison with cerebral total 
infarct size of IR rats received vehicle (group II: 
292±21 mm3), IR rats received candesartan at 0.1 
or 0.5 mg/kg had significantly lower total infarct 
size (group III: 136±21 mm3 P=0.001, and group 
IV: 138±24 mm3 respectively, P=0.001, figure 1). 
Furthermore, pre-ischemic AT1 receptor blockade 
with candesartan at 0.1 or 0.5 mg/kg, significantly 
reduced cortical and striatal infarction sizes 
compared to IR rats received vehicle (P=0.001 
for both figure 2 and figure 3).
Tissue Swelling
Occurring ischemia produced considerable 
tissue swelling in IR rats received vehicle (group II: 
12.4±1.1%). Pre-ischemic AT1 receptor blockade 
Figure 1: Tissue swelling (a) and total infarct size (b) in the 
studied groups. Values are mean±SEM of eight rats in each 
group. *P<0.05, **P<0.001 significant as compared with the 
respective vehicle-treated control rats (group II).                                           
Figure 2: Representative brain slices stained with TTC in 
the studied groups. Ischemic regions are white and non-
ischemic regions are red colored.                                                                                                                          
Figure 3: Cortical (a) and striatal (b) infarct sizes in the 
studied groups. Values are mean±SEM of eight rats in each 
group. *P<0.01 significant as compared with vehicle-treated 
control rats (group II).                                                                                                                        
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with candesartan significantly decreased tissue 
swelling by 47.6 % at 0.1 mg/kg (group III, P=0.04) 
and 53.6% at 0.5 mg/kg (group IV, P=0.02) 
respectively (figure 1).
 Discussion                                                                                      
The results of this study revealed that the blockade 
of AT1 receptors, reduced cortical and striatal infarct 
sizes and improved neurological motor deficits. 
These findings are in agreement with reports from 
other investigators demonstrating that AT1 receptor 
blockade with candesartan reduced infarct size in 
transient cerebral ischemia in normotensive rats,18 
or permanent focal ischemia in adult spontaneously 
hypertensive rats.15 Transient or permanent MCA 
occlusion in AT1 knockout mice, as compared with 
normal type, produced smaller core in the ischemic 
area with a much larger penumbra.19 In contrast, 
Groth et al.20 and Sugawara et al.21 reported that 
inhibition of AT1 receptors by pretreatment of the 
animal with candesartan did not reduce ischemic 
brain injuries in the rat. This controversy is believed 
to be related to hypotension observed before, during 
and after ischemia.20 The present study also showed 
that the protective effects of candesartan against 
brain injuries and edema at high dose (0.5 mg/kg) 
was not significantly different with non-hypotensive 
dose of this drug (0.1 mg/kg). Candesartan at 
0.5 mg/kg could significantly decrease MAP 
before ischemia. During cerebral ischemia, the 
mechanisms regulating CBF are impaired leaving 
the dependency of local CBF on arterial blood 
pressure.22 Hence severe hypotension, possibly 
did mask the protective effects of AT1 receptor 
blockade. It seems that there is a positive correlation 
between the level of MAP and the protective effects 
of AT1 receptor blockade and profound drop in 
MAP hypoperfuses the ischemic area of the brain 
and prevent the protective effects of AT1 receptor 
blockade against IR injuries.
Various mechanisms might be responsible for 
the beneficial effects of AT1 receptor blockade 
in brain ischemia. Such effects might be partly 
attributed to their stabilization actions on the 
impaired cerebrovascular autoregulation in 
penumbra. In addition, they might be due to effects 
on the nucleus solitary tract that contributes to 
the regulation of CBF by a reduction of central 
sympathetic tone.23 Anti-apoptotic mechanisms 
might be involved in the protective effects of AT1 
receptor blockade. Ang II, via activation of AT1 
receptors, may provoke apoptosis of ischemic 
neurons.24 Thus, anti- apoptotic effects of AT1 
receptor blockade may have beneficial effects 
on ischemic brain injury.
The beneficial effects of AT1 blockade might 
also be attributed to the reduction of reactive 
oxygen species (ROS) production.21 Cerebral 
ischemia is associated with excessive production 
of ROS, especially superoxide. The production 
of ROS initiates chain reactions causing cellular 
macromolecular damage, and promotes 
the mitochondrial apoptosis pathway, which 
ultimately leads to cell death.25The stimulation 
of AT2 receptors might also be involved in the 
beneficial effects of AT1 receptor blockade. 
The blockade of AT1 receptors may slow down 
the neurodegenerative events in ischemic 
brain tissues by allowing Ang II to increase the 
stimulation of AT2 receptors.
26
Brain edema is a life–threatening complication 
of cerebral infarction and aggravates the primary 
ischemic injury to the brain by negatively affecting 
the perfusion of penumbra due to the compression 
of cerebral vasculature via increased intracranial 
pressure and herniation.2,3 The results of the 
present study demonstrated that induction of 
focal cerebral ischemia significantly increased 
tissue swelling of ischemic hemisphere. While, 
pre-ischemic blocking of AT1 receptors by 
candesartan significantly reduced swelling in the 
ischemic hemisphere and decreased ischemic 
edema. Other reports about the evaluation of 
tissue swelling of the ischemic hemispheres, 
from TTC method15,23,27 supports the results of 
the present study. The protective effects of AT1 
receptor blockade on ischemic brain edema were 
demonstrated in other experimental models and 
animal species. Blezer and colleagues showed 
that AT1 receptor inhibition by non-hypotensive 
dose of losartan reduced cerebral edema and 
markedly prolonged survival in SHR.28 In addition, 
the inhibition of AT1 receptors by losartan 
prevented brain edema following global cerebral 
ischemia in the cat.29 These results support the 
conclusions of the present study that Ang II and 
AT1 receptors might be involved in the formation 
of brain edema during I/R injuries.
The mechanisms of the beneficial effects of 
AT1 receptor blockade on ischemic brain edema 
have not been fully elucidated. It seems that non-
hypotensive mechanisms play a major role, since 
the present study as well as others28,29 showed 
that the protective effects of AT1 receptor blockade 
was achieved without hypotension. Mechanisms 
such as normalizing of endothelial NO 
synthase activity, and reduced cerebrovascular 
inflammation might also be involved in such 
protective effects.30 Furthermore, Ang II via 
AT1 receptors may enhance cerebrovascular 
permeability and edema by production of 
ROS and matrix metalloproteinases.31,32 Thus, 
blocking of AT1 receptors, may reduce ischemic 
edema by the protective effects on BBB integrity 
and lowering its permeability during ischemia. 
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However, the clarification of this postulation 
needs more study. 
 Conclusion                                                                                      
The results of this study demonstrate that RAS 
participates in the exacerbation of cerebral I/R 
injuries, and Ang II may play an important role as 
mediator in ischemic brain injury by stimulating of AT1 
receptors. Hence, the inhibition of RAS by an AT1 
receptor blocker reduced cerebral infarction size, 
tissue swelling and improved neurological motor 
activity in rats exposed to transient MCA occlusion. 
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